Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1980 1
1981 1
1982 2
1983 1
1984 3
1985 3
1986 1
1989 5
1990 10
1991 4
1992 1
1993 4
1994 5
1996 4
1997 11
1998 5
1999 5
2000 6
2001 4
2002 2
2003 6
2004 4
2005 1
2006 2
2007 6
2008 6
2009 2
2010 5
2011 4
2012 2
2013 4
2014 3
2016 7
2017 5
2018 3
2019 6
2020 16
2021 3
2022 8
2023 9
2024 13
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

182 results

Results by year

Filters applied: . Clear all
Page 1
Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma.
Rade M, Grieb N, Weiss R, Sia J, Fischer L, Born P, Boldt A, Fricke S, Franz P, Scolnick J, Venkatraman L, Xu S, Kloetzer C, Heyn S, Kubasch AS, Baber R, Wang SY, Bach E, Hoffmann S, Ussmann J, Schetschorke B, Hell S, Schwind S, Metzeler KH, Herling M, Jentzsch M, Franke GN, Sack U, Köhl U, Platzbecker U, Reiche K, Vucinic V, Merz M. Rade M, et al. Among authors: franz p. Nat Cancer. 2024 Sep;5(9):1318-1333. doi: 10.1038/s43018-024-00763-8. Epub 2024 Apr 19. Nat Cancer. 2024. PMID: 38641734
Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma.
Fischer L, Grieb N, Born P, Weiss R, Seiffert S, Boldt A, Fricke S, Franz P, Heyn S, Kubasch AS, Baber R, Weidner H, Wang SY, Bach E, Hoffmann S, Ussmann J, Kirchberg J, Hell S, Schwind S, Metzeler KH, Herling M, Jentzsch M, Franke GN, Sack U, Reiche K, Köhl U, Platzbecker U, Vucinic V, Merz M. Fischer L, et al. Among authors: franz p. Leukemia. 2024 Feb;38(2):372-382. doi: 10.1038/s41375-023-02129-y. Epub 2024 Jan 6. Leukemia. 2024. PMID: 38184754 Free PMC article.
Tibial tubercle avulsion fractures in children.
Franz P, Luderowski E, Tuca M. Franz P, et al. Curr Opin Pediatr. 2020 Feb;32(1):86-92. doi: 10.1097/MOP.0000000000000870. Curr Opin Pediatr. 2020. PMID: 31895159 Review.
An allosteric inhibitor of RhoGAP class-IX myosins suppresses the metastatic features of cancer cells.
Kyriazi D, Voth L, Bader A, Ewert W, Gerlach J, Elfrink K, Franz P, Tsap MI, Schirmer B, Damiano-Guercio J, Hartmann FK, Plenge M, Salari A, Schöttelndreier D, Strienke K, Bresch N, Salinas C, Gutzeit HO, Schaumann N, Hussein K, Bähre H, Brüsch I, Claus P, Neumann D, Taft MH, Shcherbata HR, Ngezahayo A, Bähler M, Amiri M, Knölker HJ, Preller M, Tsiavaliaris G. Kyriazi D, et al. Among authors: franz p. Nat Commun. 2024 Nov 16;15(1):9947. doi: 10.1038/s41467-024-54181-6. Nat Commun. 2024. PMID: 39550360 Free PMC article.
Teclistamab impairs detection of BCMA CAR-T cells.
Glatte B, Wenk K, Grahnert A, Friedrich M, Merz M, Vucinic V, Fischer L, Reiche K, Alb M, Hudecek M, Franz P, Fricke S, Platzbecker U, Koehl U, Sack U, Boldt A, Hauschildt S, Weiss R. Glatte B, et al. Among authors: franz p. Blood Adv. 2023 Aug 8;7(15):3842-3845. doi: 10.1182/bloodadvances.2023009714. Blood Adv. 2023. PMID: 37026812 Free PMC article. No abstract available.
Optimizing CAR-T treatment: A T2EVOLVE guide to raw and starting material selection.
Navarro S, Moukheiber C, Inogés Sancho S, Ruiz Guillén M, López-Díaz de Cerio A, Sanges C, Tanaka T, Arnould S, Briones J, Dolstra H, Hudecek M, Choudhary R, Schapitz I, Juan M, Worel N, Ammar D, Luu M, Müller M, Schroeder B, Negre H, Franz P. Navarro S, et al. Among authors: franz p. Mol Ther. 2024 Nov 12:S1525-0016(24)00744-5. doi: 10.1016/j.ymthe.2024.11.017. Online ahead of print. Mol Ther. 2024. PMID: 39533710 Free article. Review.
Accelerating development of engineered T cell therapies in the EU: current regulatory framework for studying multiple product versions and T2EVOLVE recommendations.
Ammar D, Schapitz I, Luu M, Hudecek M, Meyer M, Taps T, Schröder B, Ivics Z, Sanges C, Franz P, Koehl U, Negre H, Johanna I, Awigena-Cook J. Ammar D, et al. Among authors: franz p. Front Immunol. 2023 Nov 24;14:1280826. doi: 10.3389/fimmu.2023.1280826. eCollection 2023. Front Immunol. 2023. PMID: 38077331 Free PMC article. Review.
182 results